DrugsControl Media Services

News Detail

US FDA approves Syfovre – first treatment for geographic atrophy, leading cause of blindness (18-02-2023)

Maryland, 17 Feb 2023: The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals Inc's drug to treat an advanced eye disorder that is one of the leading causes of blindness globally, the company said on Friday.


The drug, which would be sold......
View Details

Source : Reuters
U.S. Food and Drug Administration Apellis Pharmaceuticals Inc's approved blindness Syfovre geographic atrophy (GA) anti-VEGF (vascular endothelial growth factor) therapies

Related News